Keywords: Bristol-Myers Squibb, Avagacestat, Alzheimer's disease, Discontinuation, Bapineuzumab, Solanezumab, MK-8931

Another Alzheimer's drug hits the dust as Bristol-Myers drops avagacestat development

Article | 04 December 2012

Print This

In yet another research disappointment, US drug major Bristol-Myers Squibb (NYSE: BMY) recently assessed data on avagacestat from a completed ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in